PLASMA STEROID AND PROTEIN HORMONE CONCENTRATIONS IN PATIENTS WITH PROSTATIC CARCINOMA, BEFORE AND DURING OESTROGEN THERAPY

1976 ◽  
Vol 81 (2) ◽  
pp. 409-426 ◽  
Author(s):  
M. E. Harper ◽  
W. B. Peeling ◽  
T. Cowley ◽  
B. G. Brownsey ◽  
M. E. A. Phillips ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Prostatic Cancer ◽  
Prostatic Carcinoma ◽  
Follicle Stimulating Hormone ◽  
Prolactin Secretion ◽  
Prostatic Hyperplasia ◽  
Benign Disease ◽  
Plasma Testosterone ◽  
Plasma Prolactin ◽  
Plasma Oestradiol

ABSTRACT Plasma testosterone, androstenedione, oestradiol-17β, follicle stimulating hormone (FSH) and luteinizing hormone (LH) were not significantly different in patients with prostatic cancer, with benign prostatic hyperplasia or in patients without prostatic disease. Plasma prolactin concentrations were significantly lower in the patients with benign disease than those with prostatic carcinoma. Endocrine therapy in the form of stilboestrol administration significantly decreased plasma levels of testosterone, oestradiol-17β, FSH and LH within 7 days of the treatment. After 7 days therapy prolactin levels increased significantly in all patients studied. Changes in growth hormone concentrations were more varied in response to stilboestrol, being elevated in several patients and remaining unchanged in others. Treatment of a few prostatic carcinoma patients who were receiving stilboestrol therapy with CB154, an inhibitor of prolactin secretion, brought an immediate decrease in prolactin levels which was sustained. Plasma testosterone, androstenedione and growth hormone were unchanged in these patients but a significant decrease in plasma oestradiol-17β was noted in two patients during CB154 administration.

A Chronobiological Study of Melatonin, Cortisol Growth Hormone and Prolactin Secretion in Cluster Headache

Cephalalgia ◽  
1984 ◽  
Vol 4 (4) ◽  
pp. 213-220 ◽  
Author(s):  
Guy Chazot ◽  
Bruno Claustrat ◽  
Jocelyne Brun ◽  
Daniel Jordan ◽  
Geneviève Sassolas ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Cluster Headache ◽  
Prolactin Secretion ◽  
Temporal Organization ◽  
Plasma Prolactin ◽  
Melatonin Rhythm ◽  
Plasma Melatonin ◽  
Sleep Recording ◽  
Plasma Gh ◽  
Headache Patients

The temporal organization of plasma melatonin. cortisol. growth hormone (GH) and prolactin secretion was examined in healthy rested controls and in patients suffering from episodic cluster headache. Eleven patients with typical cluster headache (10 men, 1 female) and 8 male controls were studied over a 24–h period: blood was collected at 2–h intervals during the day and at l-h intervals at night. Plasma melatonin. cortisol, GH and prolactin levels were determined by radioimmunoassay. Most of the cluster headache patients showed a decrease in nocturnal melatonin secretion and the melatonin rhythm was even completely abolished in one patient. Chronobiological analysis of the cluster headache patients' 24–h plasma melatonin profile showed a significant decrease in amplitude and mesor: these were 58.7 pg/ml and 34.4 pg/ml respectively in control subjects, versus 18.7 pg/ml and 17.6 pg/ml for the patients. In addition. patients showed a significant phase-advance in their melatonin rhythm For cortisol, the rhythm appeared slightly blunted in the cluster headache group and was significantly phase-advanced. The plasma prolactin profile showed no significant alteration, but for plasma GH the nocturnal peak was advanced in some patients: in the absence of sleep recording, however, no conclusion could be drawn. Results from this study suggest a neuroendocrine dysregulation in cluster headache in the endogenous clock which controls the pineal rhythmicity.

Growth hormone and prostatic tumours: localization using a monoclonal human growth hormone antibody

1984 ◽  
Vol 103 (3) ◽  
pp. 311-315 ◽  
Author(s):  
P. E. C Sibley ◽  
M. E. Harper ◽  
W. B. Peeling ◽  
K. Griffiths
Keyword(s):  
Growth Hormone ◽  
Connective Tissue ◽  
Prostatic Carcinoma ◽  
Human Growth ◽  
Prostatic Hyperplasia ◽  
Immunocytochemical Staining ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Immunocytochemical Detection ◽  
Human Prolactin

ABSTRACT The immunocytochemical detection of endogenous human GH and the binding of exogenously applied human GH in tumour tissue from patients with benign prostatic hyperplasia or prostatic carcinoma is reported. Monoclonal human GH antibody binding was exclusively to the connective tissue in both benign and carcinomatous specimens. Specificity control experiments indicated that the antibody could be absorbed with human GH but not with human prolactin. Preincubating the sections with human GH considerably altered the immunocytochemical staining, reducing the reaction product within the connective tissue in a concentration-dependent manner and revealing a binding site for GH within the cytoplasm of epithelial cells. J. Endocr. (1984) 103, 311–315

PITUITARY HORMONES IN WOMEN WITH CHRONIC RENAL FAILURE: THE EFFECT OF CHRONIC INTERMITTENT HAEMO-AND PERITONEAL DIALYSIS

1975 ◽  
Vol 80 (2) ◽  
pp. 237-246 ◽  
Author(s):  
K. Ølgaard ◽  
C. Hagen ◽  
A. S. McNeilly
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Chronic Renal Failure ◽  
Significant Influence ◽  
Follicle Stimulating Hormone ◽  
Pituitary Hormones ◽  
Plasma Prolactin ◽  
Significant Difference ◽  
Before And After

ABSTRACT Measurements of plasma prolactin (hPr), growth hormone (HGH), thyrotrophin (TSH), luteinizing (LH) – and follicle stimulating hormone (FSH) were performed in 20 women with chronic renal failure on regular dialysis. There was no significant difference in any of the hormone levels before and after the dialysis and no significant influence of the type of dialysis (haemodialysis and peritoneal dialysis) or the time of dialysis. Higher levels of plasma prolactin was found in the women on peritoneal dialysis than in the haemodialyzed women presumably due to the medical treatment. In the peritoneally dialyzed group four women had irregular menstruations and normal gonadotrophic levels, but elevated hPr and it is suggested that this finding is similar to that seen in the amenorrhoeagalactorrhoea syndrome, where hPr presumably in some way have anti-gonadotrophic actions at the gonadal level.

Mechanism of serotonin effects on prolactin and growth hormone secretion in domestic fowl

1983 ◽  
Vol 104 (3) ◽  
pp. 266-271 ◽  
Author(s):  
T. R. Hall ◽  
S. Harvey ◽  
A. Chadwick
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Secretion ◽  
Prolactin Secretion ◽  
Brain Serotonin ◽  
Plasma Prolactin ◽  
Serotonin Content ◽  
Pituitary Glands ◽  
Releasing Factors

Abstract. Brain serotonin levels were increased in immature chickens by ip injection of pargyline (75 mg/kg) and clorgyline (5 mg/kg) and by l-tryptophan (100 mg/kg) and imipramine (10 mg/kg) treatment. These treatments increased the circulating prolactin level and reduced the concentration of plasma growth hormone (GH). Treatment with para-chlorophenylalanine (PCPA, 100 mg/kg) reduced the brain serotonin content and the level of plasma prolactin. Treatment with these drugs in vivo similarly affected the basal level of prolactin release from pituitary glands in vitro, although it did not affect the basal level of GH release. The in vitro responsiveness of the pituitary gland to hypothalamic stimuli eliciting prolactin secretion was increased by in vivo pargyline and combined tryptophan: imipramine treatment but reduced by PCPA administration. The in vitro GH response to hypothalamic stimulation was reduced after the in vivo injection of pargyline, clorgyline and tryptophan: imipramine. The hypothalami from clorgyline and tryptophan: imipramine treated birds induced a greater stimulation of in vitro prolactin secretion from control pituitary glands than hypothalami from controls birds, whereas the GH releasing activity was reduced. These results suggest that serotonin stimulates prolactin secretion in chickens by increasing pituitary responsiveness to hypothalamic releasing factors and by increasing the prolactin releasing activity of the hypothalamus. Serotonin appears to suppress GH secretion by reducing pituitary sensitivity to releasing factors and by reducing hypothalamic GH releasing activity.

Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man

1980 ◽  
Vol 93 (2) ◽  
pp. 149-154 ◽  
Author(s):  
F. Cavagnini ◽  
C. Invitti ◽  
M. Pinto ◽  
C. Maraschini ◽  
A. Di Landro ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Venous Blood ◽  
Repeated Administration ◽  
Tolerance Test ◽  
Prolactin Secretion ◽  
Aminobutyric Acid ◽  
Plasma Prolactin ◽  
Gamma Aminobutyric Acid ◽  
Insulin Tolerance ◽  
Before And After

Abstract. A single oral dose of 5 g gamma aminobutyric acid (GABA) was given to 19 subjects and serial venous blood samples were obtained before and 3 h after drug administration. A placebo was administered to 18 subjects who served as controls. GABA caused a significant elevation of plasma growth hormone levels (P < 0.001), but did not consistently alter plasma prolactin concentration since only 5 out of 15 subjects showed an increase of the hormone. Eight additional subjects were submitted to an insulin tolerance test before and after per os administration of 18 g GABA daily for 4 days. Protracted GABA treatment significantly blunted the response of growth hormone and enhanced that of prolactin to insulin hypoglycaemia (P < 0.01). These results indicate that pharmacological doses of GABA affect growth hormone and prolactin secretion in man. The precise nature of GABA's effects as well as its mechanism of action remains to be clarified.

Serum Prostate-Specific Antigen Determination in Prostatic Carcinoma

1987 ◽  
Vol 2 (3) ◽  
pp. 184-186 ◽  
Author(s):  
Alessandro Tizzani ◽  
Giovanni Casetta ◽  
Paolo Piana ◽  
Maurizio Bellina ◽  
Ferdinando Pecchio ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Number Of Patients ◽  
Antigen Determination ◽  
Early Predictor

Prostate-specific antigen (PSA) is a tissue-specific glycoprotein identified by Wang in 1979. It is synthesized in the prostate independently of prostatic acid phosphatase (PAP). A total of 199 subjects were divided into four groups: controls aged less than 50 years, controls aged more than 50 years, patients with benign prostatic hyperplasia (BPH) and patients with prostatic carcinoma. PSA cut-off value was set at 10 ng/ml (mean for the BPH group plus 2 SD). With this cut-off value PSA could not be used as an early predictor of prostatic carcinoma. The association of PSA and PAP in prostatic cancer increases the number of patients with positive biological markers.

Effects of 2-hydroxyoestradiol-17β on plasma luteinizing hormone, follicle-stimulating hormone and prolactin, and nuclear translocation of pituitary oestrogen receptors in ovariectomized ewes

1982 ◽  
Vol 95 (1) ◽  
pp. 19-27 ◽  
Author(s):  
I. J. Clarke ◽  
K. Wynne ◽  
J. W. Funder ◽  
J. K. Findlay
Keyword(s):  
Luteinizing Hormone ◽  
Oestrogen Receptor ◽  
Nuclear Translocation ◽  
Follicle Stimulating Hormone ◽  
Plasma Concentrations ◽  
Receptor Occupancy ◽  
Prolactin Secretion ◽  
Plasma Prolactin ◽  
Oestrogen Receptors ◽  
Nuclear Compartment

The ability of oestradiol-17β (OE2) and 2-hydroxyoestradiol (2OH-OE2) to translocate pituitary oestrogen receptors to the nuclear compartment and to affect plasma concentrations of LH, FSH and prolactin was studied in ovariectomized ewes. Mean (± s.e.m.) nuclear oestrogen receptor levels (% of total pituitary oestrogen receptors) after intracarotid injections of 1·25 μg OE2, 400 μg 2OH-OE2 or vehicle were 8·7±2·3, 16·9 ± 3·2 and 0·8±0·1% respectively. Whereas 1·25 or 12·5 μg OE2 significantly lowered plasma LH and FSH, 400 μg 2OH-OE2 did not affect plasma LH or FSH levels. Injection of 4000 μg 2OH-OE2, however, significantly affected plasma LH and FSH. Plasma prolactin levels were not significantly affected by the treatments. These data indicate a discrepancy between oestrogen receptor occupancy and effects on gonadotrophin and prolactin secretion after injection of catechol oestrogen.

Effect of 1–5 Hydroxytryptophan Infusion on Growth Hormone and Prolactin Secretion in Man

1977 ◽  
Vol 45 (3) ◽  
pp. 588-593 ◽  
Author(s):  
IOANA LANCRANJAN ◽  
ANNA WIRZ-JUSTICE ◽  
W. PÜHRINGER ◽  
E. DEL POZO
Keyword(s):  
Growth Hormone ◽  
Prolactin Secretion
Sign in / Sign up

Export Citation Format

Share Document